Bio Preventive Medicine Corp., an innovative professional in vitro diagnostic (IVD) manufacturer, announced today (31st) that DNlite-IVD103—the world's first diagnostic test designed to prevent the rapid progression of Diabetic Kidney Disease (DKD)—has successfully secured market authorization from the Medical Device Authority (MDA) of Malaysia. The company is currently aggressively establishing its sales and distribution channels across the Southeast Asian market.
Related News
BPM's DNlite-IVD103 Secures Regulatory Approval from UAE MoHAP, Accelerating Middle East Market Penetration
BPM's DNlite-IVD103 Secures Regulatory Approval from UAE MoHAP, Accelerating Middle East Market Penetration
2024/02/27
Press
Expanding the ASEAN Footprint: BPM Secures Regulatory Approval in Indonesia for DNlite-IVD103
Expanding the ASEAN Footprint: BPM Secures Regulatory Approval in Indonesia for DNlite-IVD103
2024/05/13
Press
BPM’s DNlite-IVD103 Receives TFDA Class III Approval, Becoming Taiwan’s First Precision Diagnostic for Diabetic Kidney Disease
BPM’s DNlite-IVD103 Receives TFDA Class III Approval, Becoming Taiwan’s First Precision Diagnostic for Diabetic Kidney Disease
2024/01/13
Press